Disease · MONDO_0006226

gastric mucosa-associated lymphoid tissue lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gastric mucosa-associated lymphoid tissue lymphoma. Diseases, record MONDO_0006226. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006226

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gastric mucosa-associated lymphoid tissue lymphoma; Open Targets
Open Targets ID: MONDO_0006226; Open Targets
Other names: MALT lymphoma of stomach, MALT lymphoma of the stomach, MALToma of stomach, MALToma of the stomach, gastric MALT lymphoma, gastric MALToma, primary MALT lymphoma of stomach, primary MALT lymphoma of the stomach, primary gastric B-cell MALT lymphoma, primary gastric MALT lymphoma, stomach MALT lymphoma; Open Targets
NCI Thesaurus: C5266; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 14 drugs, from PMDA; Open Targets

Drugs14

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ESOMEPRAZOLE MAGNESIUM	CHEMBL5314366	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
VONOPRAZAN FUMARATE	CHEMBL2064032	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
CLARITHROMYCIN	CHEMBL1741	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
METRONIDAZOLE	CHEMBL137	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ESOMEPRAZOLE	CHEMBL1201320	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IBRITUMOMAB TIUXETAN	CHEMBL1201606	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TETRACYCLINE	CHEMBL1440	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
AMOXICILLIN	CHEMBL1082	Small molecule	Unknown	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 14

See all 14 drugs

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ATP4A	Potassium-transporting ATPase	5	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	5	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/496	Drugs and targets
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Unknown	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	1	Matrix metalloproteinase 13 inhibitor	Unknown	https://conductscience.org/library/genes/4322	Drugs and targets
MMP7	Matrilysin	1	Matrix metalloproteinase 7 inhibitor	Unknown	https://conductscience.org/library/genes/4316	Drugs and targets
MMP8	Neutrophil collagenase	1	Matrix metalloproteinase 8 inhibitor	Unknown	https://conductscience.org/library/genes/4317	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	1	B-lymphocyte antigen CD20 binding agent	Phase 2	https://conductscience.org/library/genes/931	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03219723	Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"		560	2019-03-22	Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other	AMOXICILLIN, CLARITHROMYCIN, METRONIDAZOLE, VONOPRAZAN	Its record names the disease	ClinicalTrials.gov
NCT00453102	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma	Phase 2	18	2016-01-01	Marginal Zone Lymphoma	IBRITUMOMAB TIUXETAN, RITUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT05410223	Efficacy and Safety Study of Egg Yolk Antibody in Adjuvant Treatment of Helicobacter Pylori Infection	Not applicable	100		Helicobacter Pylori Infection	AMOXICILLIN, CLARITHROMYCIN, DOXYCYCLINE, FURAZOLIDONE	Its record names the disease	ClinicalTrials.gov
NCT00327132	Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome	Not applicable	47		Gastric MALT Lymphoma	AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT07144657	Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma	Phase 2	40		MALT Lymphoma of Stomach	CLARITHROMYCIN, CYCLOPHOSPHAMIDE, ESOMEPRAZOLE, METRONIDAZOLE, TETRACYCLINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006226

GET https://conductscience.org/api/diseases/v1/MONDO_0006226/drugs

API reference For AI assistants